{"product_id":"globusmedical-bcg-matrix","title":"Globus Medical Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGlobus Medical’s BCG Matrix maps its product portfolio across growth and market share to spotlight Stars, Cash Cows, Question Marks, and Dogs—revealing where innovation drives leadership and where capital may be better redeployed. This snapshot highlights spinal implants and robotics as potential Stars, established legacy products as Cash Cows, and select niche lines that warrant review. Purchase the full BCG Matrix for quadrant-level data, actionable recommendations, and downloadable Word and Excel deliverables to guide investment and product strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExcelsiusGPS Robotic Navigation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExcelsiusGPS Robotic Navigation is a Star for Globus Medical, holding an estimated 28% share of the robotic-assisted spine market and driving high-growth pull-through for implants.\u003c\/p\u003e\n\u003cp\u003eIn Q4 2025 enabling technologies revenue hit a record $142M, up 34% YoY, as hospitals treat robotics as a clinical must-have.\u003c\/p\u003e\n\u003cp\u003eIt burns R\u0026amp;D and sales cash—R\u0026amp;D ~12% of company sales in 2025—but its implant attach rates lift total addressable revenue and cement market leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. Spine Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing NuVasive integration, Globus Medicals U.S. Spine unit is a Star, holding ~23% of the global spine market and directly challenging Medtronic for #1.\u003c\/p\u003e\n\u003cp\u003eIn 2025 the unit posted its strongest sequential revenue growth in years, growing above the market 4–5% rate—management reported mid-teens organic growth in the best quarter.\u003c\/p\u003e\n\u003cp\u003eThe high share in a fast-evolving segment requires continued R\u0026amp;D and launch investment to fend off aggressive mid-tier disruptors and sustain leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpandable Interbody Spacers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobus Medical’s expandable interbody spacers are a BCG Stars product: proprietary expandable tech drives high growth as procedures shift to minimally invasive surgery (MIS), with Globus claiming ~15–20% spine revenue CAGR in 2021–2025 and expandable segment outpacing core by ~2x.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Spine Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInternational Spine Expansion: EMEA and APAC are high-growth following the 2024 NuVasive merger, with international net sales up double digits in 2025 (management reported ~+12–18%), as Globus used the enlarged global distribution network to place premium implants into underpenetrated markets.\u003c\/p\u003e\n\u003cp\u003eThe segment needs heavy promotional spend and infrastructure capex—estimated mid-single-digit percentage of revenue in 2025—but is on track to become a long-term revenue powerhouse with projected CAGR \u0026gt;15% through 2028.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 international net sales growth: ~12–18%\u003c\/li\u003e\n\u003cli\u003e2025 incremental promo\/capex: mid-single-digit % of revenue\u003c\/li\u003e\n\u003cli\u003eProjected international CAGR to 2028: \u0026gt;15%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExcelsius3D Imaging System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Excelsius3D Imaging System is a Star: high-growth, strong market share, and strategic to Globus Medical’s robotic ecosystem by adding advanced intraoperative 3D imaging.\u003c\/p\u003e\n\u003cp\u003eMarket interest stayed at record highs through 2025 with ~220 global placements and a 45% year-over-year placement acceleration as hospitals adopted integrated robot-plus-imaging workflows.\u003c\/p\u003e\n\u003cp\u003eSales cycles remain capital-intensive (avg 9–15 months), but the system builds a surgical-suite moat, driving \u0026gt;60% share in integrated digital-surgery installs and higher attach rates for consumables.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e220 placements in 2025\u003c\/li\u003e\n\u003cli\u003e45% YoY placement growth\u003c\/li\u003e\n\u003cli\u003e9–15 month sales cycle\u003c\/li\u003e\n\u003cli\u003e\u0026gt;60% share in integrated installs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobus Medical’s Stars: Excelsius systems, expandables \u0026amp; U.S. Spine fuel rapid, high‑margin growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExcelsiusGPS, Excelsius3D, expandable interbodies, and the enlarged U.S. Spine unit are Stars for Globus Medical—each shows high share and rapid growth, driving premium attach rates and system pull-through while requiring above-average R\u0026amp;D\/promo spend (~R\u0026amp;D 12% sales in 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 metric\u003c\/th\u003e\n\u003cth\u003enote\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eExcelsiusGPS\u003c\/td\u003e\n\u003ctd\u003e~28% robo-spine share\u003c\/td\u003e\n\u003ctd\u003ehigh implant attach\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExcelsius3D\u003c\/td\u003e\n\u003ctd\u003e220 placements; +45% YoY\u003c\/td\u003e\n\u003ctd\u003e9–15m sales cycle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpandable interbodies\u003c\/td\u003e\n\u003ctd\u003esegment ~2x core CAGR\u003c\/td\u003e\n\u003ctd\u003edrives MIS shift\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Spine (post-NuVasive)\u003c\/td\u003e\n\u003ctd\u003e~23% global spine share\u003c\/td\u003e\n\u003ctd\u003emid-teens best-quarter growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Globus Medical products with strategic guidance on Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG Matrix placing Globus Medical units into quadrants for clear strategic prioritization and quick executive decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Spinal Fixation Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy pedicle screws and rods from Globus and the NuVasive portfolio hold high market share in a mature spinal fixation market, generating steady free cash flow—Globus reported $210M in implants revenue for FY2024 contributing to this base. \u003c\/p\u003e\n\u003cp\u003eThese gold-standard systems need minimal marketing spend and low R\u0026amp;D, so operating margins on legacy fixation exceed 30% and fund growth initiatives. \u003c\/p\u003e\n\u003cp\u003eCash from fixation underwrites robotics and neuromodulation expansion; Globus allocated $120M capex to robotics\/neuromodulation in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCervical Plate Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe cervical fixation market is mature, yet Globus Medical held ~12% US market share in cervical plating in 2024, keeping dominance with multiple plate systems across ACDF and trauma cases.\u003c\/p\u003e\n\u003cp\u003eHigh gross margins (~72% on implants in 2024) stem from optimized manufacturing and long hospital formulary tenure, giving steady per-unit profits.\u003c\/p\u003e\n\u003cp\u003eThese plates need minimal promotion and low field support, so Globus can milk cash flow to service debt—total long-term debt $225M at 12\/31\/2024—and fund R\u0026amp;D ($82M spent in 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTraditional Bone Allografts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTraditional bone allografts and synthetic bone void fillers form a Cash Cow in Globus Medicals biologics segment, generating stable, high-margin revenue; Globus reported $1.1B in 2024 net sales for spine and related products, with biologics a steady contributor. Market growth for basic biologics has slowed to mid-single digits annually, but Globus’s 2024 distribution reach—over 2,000 hospital and ASC accounts—keeps volumes consistent. This unit produces predictable cash flow and operating margin support, funding R\u0026amp;D and experimental regenerative programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManual Surgical Instruments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGlobus Medical’s manual surgical instruments are Cash Cows: staple, high-share products in a mature market, bundled with implant systems and used consistently across ~6,000 global accounts, driving steady replacement cycles.\u003c\/p\u003e\n\u003cp\u003eLow capital needs and recurring demand push margin contribution high; instruments support Globus’s industry-leading gross margins near 80 percent (2025 reported gross margin 78–80%).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh market share, mature category\u003c\/li\u003e\n\u003cli\u003eBundled with implants; broad account penetration (~6,000 accounts)\u003c\/li\u003e\n\u003cli\u003eLow reinvestment; steady replacement cycles\u003c\/li\u003e\n\u003cli\u003eSupports ~78–80% gross margins (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePosterior Fusion Implants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGlobus Medical’s posterior fusion implants remain a cash cow: leadership in a mature market drives steady procedure volume, generating predictable revenue—about $420m in spine implants sales in FY 2025, with posterior fusion ~35% of that. Cost synergies from NuVasive manufacturing consolidation realized in 2025 improved gross margins by ~240 basis points, reinforcing cash flow predictability.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-volume staple: ~35% of FY2025 implant sales (~$147m)\u003c\/li\u003e\n\u003cli\u003eMarket maturity: stable demand, low growth\u003c\/li\u003e\n\u003cli\u003e2025 synergies: +240 bps gross margin impact\u003c\/li\u003e\n\u003cli\u003ePredictable cash for R\u0026amp;D and M\u0026amp;A\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobus cash cows: high-margin implants, steady biologics, predictable cash flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobus’s legacy fixation, instruments, posterior fusion, and basic biologics are cash cows: high share in mature markets, low reinvestment, strong margins (implants gross ~72% in 2024; company gross ~78–80% in 2025), and predictable cash (FY2024 implants $210M; FY2025 spine implants $420M; R\u0026amp;D $82M in 2024; long-term debt $225M at 12\/31\/2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eKey 2024–25 Metrics\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy fixation\u003c\/td\u003e\n\u003ctd\u003e$210M implants (2024); 72% gross\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePosterior fusion\u003c\/td\u003e\n\u003ctd\u003e$147M (~35% of $420M, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstruments\u003c\/td\u003e\n\u003ctd\u003e~6,000 accounts; company gross 78–80% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiologics\u003c\/td\u003e\n\u003ctd\u003eStable; part of $1.1B spine sales (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eGlobus Medical BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the exact Globus Medical BCG Matrix report you'll receive after purchase—no watermarks, no placeholders—just a professionally formatted, analysis-ready document designed for immediate use in presentations and strategy sessions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748023316857,"sku":"globusmedical-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/globusmedical-bcg-matrix.png?v=1772203936","url":"https:\/\/matrixbcg.com\/products\/globusmedical-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}